Promising Outlook for Intellia Therapeutics’ Nex-z in ATTR-CM Treatment Backed by Safety and Patient Interest

TIPRANKS11-26 19:17

JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on NTLA stock, giving a Buy rating on November 18. Debanjana Chatterj...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486734670?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-26 19:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486734670","market":"us","top_or_hot":-1,"title":"Promising Outlook for Intellia Therapeutics’ Nex-z in ATTR-CM Treatment Backed by Safety and Patient Interest","media":"TIPRANKS","content":"<div>\n<p>JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on NTLA stock, giving a Buy rating on November 18. Debanjana Chatterj...</p>\n\n<a href=\"https://www.tipranks.com/news/blurbs/promising-outlook-for-intellia-therapeutics-nex-z-in-attr-cm-treatment-backed-by-safety-and-patient-interest?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Promising Outlook for Intellia Therapeutics’ Nex-z in ATTR-CM Treatment Backed by Safety and Patient Interest</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPromising Outlook for Intellia Therapeutics’ Nex-z in ATTR-CM Treatment Backed by Safety and Patient Interest\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-26 19:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/blurbs/promising-outlook-for-intellia-therapeutics-nex-z-in-attr-cm-treatment-backed-by-safety-and-patient-interest?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on NTLA stock, giving a Buy rating on November 18. Debanjana Chatterj...</p>\n\n<a href=\"https://www.tipranks.com/news/blurbs/promising-outlook-for-intellia-therapeutics-nex-z-in-attr-cm-treatment-backed-by-safety-and-patient-interest?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CM","symbol_name":"加拿大帝国商业银行","start_time":0,"source_url":"https://www.tipranks.com/news/blurbs/promising-outlook-for-intellia-therapeutics-nex-z-in-attr-cm-treatment-backed-by-safety-and-patient-interest?utm_source=itigerup.com&utm_medium=referral","article_id":"2486734670","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-outlook-for-intellia-therapeutics-nex-z-in-attr-cm-treatment-backed-by-safety-and-patient-interest?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2486734670","pubTimestamp":1732619824,"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on NTLA stock, giving a Buy rating on November 18. Debanjana Chatterj...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CM":"加拿大帝国商业银行","NTLA":"Intellia Therapeutics Inc","BK4535":"淡马锡持仓","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4207":"综合性银行","BK4585":"ETF&股票定投概念","BK4556":"基因编辑","BK4139":"生物科技","BK4588":"碎股","LU1861558580.USD":"日兴方舟颠覆性创新基金B"},"translate_title":"在安全性和患者利益的支持下，Intellia Therapeutics的Nex-z在ATTR-CM治疗中前景广阔","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CM":1,"NTLA":1},"content_text":"JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on NTLA stock, giving a Buy rating on November 18. Debanjana Chatterj...","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486734670"}